NasdaqCM - Delayed Quote USD

Aptose Biosciences Inc. (APTO)

1.1600 -0.0600 (-4.92%)
At close: April 25 at 4:00 PM EDT
1.2100 +0.05 (+4.31%)
After hours: April 25 at 7:30 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. William G. Rice Ph.D. Chairman, President, CEO & Chief Accounting Officer 651.9k -- 1959
Mr. Fletcher Payne Senior VP, CFO, Chief Business Officer & Secretary 470.9k -- 1963
Dr. Rafael Bejar M.D., Ph.D. Senior VP & Chief Medical Officer 499.9k -- 1973
Dr. Marc Wiles Ph.D. Senior Vice President of Regulatory Affairs -- -- --
Mr. Brooks Ensign M.B.A. VP & Controller -- -- --

Aptose Biosciences Inc.

251 Consumers Road
Suite 1105
Toronto, ON M2J 4R3
Canada
647 479 9828 https://www.aptose.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
35

Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Corporate Governance

Aptose Biosciences Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 7; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 06, 2024 - May 10, 2024
Aptose Biosciences Inc. Earnings Call

Related Tickers

TFFP TFF Pharmaceuticals, Inc.
3.0500
+3.39%
 
CGTX Cognition Therapeutics, Inc.
1.9300
-3.02%
 
ALZN Alzamend Neuro, Inc.
0.7000
-1.30%
 
SXTP 60 Degrees Pharmaceuticals, Inc.
0.2336
-3.59%
 
CUE Cue Biopharma, Inc.
1.4100
-0.70%
 
DMAC DiaMedica Therapeutics Inc.
2.5300
+3.27%
 
CALC CalciMedica, Inc.
5.29
-2.94%
 
ZNTL Zentalis Pharmaceuticals, Inc.
10.99
-6.67%
 
RNXT RenovoRx, Inc.
1.2100
-1.63%
 
ONCT Oncternal Therapeutics, Inc.
8.25
-4.18%